Compositions for cell culture and methods of using the same

Patent metadata

Field	Value
Publication number	US-9416181-B2
Application number	US-201414270675-A
Country	US
Kind code	B2
Filing date	May 6, 2014
Priority date	May 6, 2013
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.

First claim

We claim:

1. A composition comprising a chemically-defined medium (CDM) and a bioflavonoid selected from the group consisting of epigallocatechin gallate (EGCG), rutin, naringin, and genistein, wherein said bioflavonoid is present in said composition at a concentration ranging from about 0.001 g/L to about 0.2 g/L.

2. The composition of claim 1 , wherein said composition is in a liquid form and is capable of culturing cells with or without dilution.

3. The composition of claim 1 , wherein said composition is in a solid form and is capable of being reconstituted with water for culturing cells.

4. A composition comprising a chemically-defined medium (CDM), a bioflavonoid selected from the group consisting of epigallocatechin gallate (EGCG), rutin, naringin, and genistein, and a plurality of recombinant cells, wherein said plurality of recombinant cells are capable of expressing a recombinant protein.

5. The composition of claim 4 , wherein said recombinant protein is an anti-TNF-alpha antibody said anti-TNF-alpha antibody having reduced levels of acidic species as compared to anti-TNF-alpha antibody produced in cell culture without said bioflavonoid.

6. The composition of claim 4 , wherein said bioflavonoid is a member selected from the group consisting of epigallocatechin gallate (EGCG), rutin, naringin, genistein and combination thereof.

7. The composition of claim 6 , wherein said bioflavonoid is epigallocatechin gallate (EGCG), wherein said epigallocatechin gallate is present in said composition at a concentration ranging from about 0.001 g/L to about 0.2 g/L.

8. The composition of claim 7 , wherein the concentration of said epigallocatechin gallate in said composition is from about 0.01 g/L to about 0.1 g/L.

9. The composition of claim 6 , wherein said bioflavonoid is rutin, in said composition at a concentration ranging from about 0.001 g/L to about 0.2 g/L.

10. The composition of claim 6 , wherein said bioflavonoid is naringin, in said composition at a concentration ranging from about 0.001 g/L to about 2 g/L.

11. The composition of claim 6 , wherein said bioflavonoid is genistein, in said composition at a concentration ranging from about 0.001 g/L to about 0.2 g/L.

12. A method for producing a polypeptide, the method comprising culturing a plurality of cells in a culture medium comprising a bioflavonoid, wherein at least one of said plurality of cells is capable of expressing said polypeptide, wherein said bioflavonoid is selected from the group consisting of epigallocatechin gallate (EGCG), rutin, naringin, and genistein, and said bioflavonoid is present in said culture medium at a concentration ranges from about 0.001 g/L to about 0.2 g/L.

13. The method of claim 12 , wherein said polypeptide is an antibody.

14. The method of claim 12 , wherein said bioflavonoid is epigallocatechin gallate (EGCG), said EGCG being present in the culture medium at a concentration of from about 0.001 g/L to about 0.2 g/L.

15. The method of claim 14 , wherein said EGCG is present in the culture medium at a concentration of from about 0.01 g/L to about 0.1 g/L.

16. The method of claim 12 , wherein said bioflavonoid is rutin, said rutin being present in the culture medium at a concentration of from about 0.001 g/L to about 0.2 g/L.

17. The method of claim 12 , wherein said bioflavonoid is naringin, said naringin being present in the culture medium at a concentration of from about 0.001 g/L to about 2 g/L.

18. The method of claim 12 , wherein said bioflavonoid is genistein, said genistein being present in the culture medium at a concentration of from about 0.001 g/L to about 0.2 g/L.

19. The method of claim 12 , wherein said bioflavonoid is added to the culture medium in a substantially pure form.

20. The method of claim 12 , wherein said bioflavonoid is added to the culture medium as a crude extract prepared from a plant or parts thereof.

21. The method of claim 12 , wherein said polypeptide is an anti-TNF-alpha antibody.

22. The method of claim 12 , wherein said polypeptide is an antibody comprising dual variable domains (DVD).

Assignees

• Abbvie Inc

Inventors

• Wang Min
• Hossler Patrick M
• Mcdermott Sean W
• Racicot Christopher
• Chemfe Kofi
• Fann John

Classifications

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K16/241 Primary

  Tumor Necrosis Factors · CPC title

• C12N5/005

  Protein-free medium · CPC title

• C12N2510/02

  Cells for production · CPC title

• A61K39/39591

  Stabilisation, fragmentation · CPC title